Hugh Brent Solvason PhD MD

Publications

• Coping with the challenges of living in an Indonesian residential institution. Wanat S, Whisnant J, Reicherter D, Solvason B, Juul S, Penrose B, Koopman C. Health Policy. 2010; 96 (1): 45-50
• Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial". O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Biol Psychiatry. 2010; 67 (2): e15-7
• Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME. Arch Gen Psychiatry. 2009; 66 (11): 1178-88
• Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Gomez RG, Posener JA, Keller J, DeBattista C, Solvason B, Schatzberg AF. Psychoneuroendocrinology. 2009; 34 (7): 1012-8
• Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial. Petersen T, Perlis RH, Ticknor C, Lohr J, Solvason HB, O'Reardon JP, Wohlreich MM, Andreotti C, Wilson M, Fava M. Psychopharmacol Bull. 2008; 41 (1): 34-45
• Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Am J Psychiatry. 2008; 165 (7): 872-80
• Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT. J Clin Psychopharmacol. 2007; 27 (6): 614-9
• Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Biol Psychiatry. 2007; 62 (11): 1208-16
• Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Biol Psychiatry. 2007; 62 (5): 429-37
• Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Neuropsychopharmacology. 2006; 31 (3): 628-36
• Cortisol circadian rhythm alterations in psychotic major depression. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF. Biol Psychiatry. 2006; 60 (3): 275-81
• The neuropsychological profile of psychotic major depression and its relation to cortisol. Gomez RG, Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF. Biol Psychiatry. 2006; 60 (5): 472-8
• A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. J Clin Psychiatry. 2005; 66 (7): 844-8
• A prospective trial of modafinil as an adjunctive treatment of major depression. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. J Clin Psychopharmacol. 2004; 24 (1): 87-90
• A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. J Clin Psychopharmacol. 2003; 23 (1): 27-30
• Predictors of response in anxiety disorders. Solvason HB, Ernst H, Roth W. Psychiatr Clin North Am. 2003; 26 (2): 411-33
• Psychological versus biological clinical interpretation: a patient with prion disease. Solvason HB, Harris B, Zeifert P, Flores BH, Hayward C. Am J Psychiatry. 2002; 159 (4): 528-37
• Agranulocytosis associated with lamotrigine. Solvason HB, Am J Psychiatry. 2000; 157 (10): 1704
• Case report: limbic system activation by intravenous lidocaine in a patient with a complex regional pain syndrome and major depression. Leong MS, Solvason HB. Pain Med. 2000; 1 (4): 358-61
• Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. DeBattista C, Solvason HB, Breen JA, Schatzberg AF. J Clin Psychopharmacol. 2000; 20 (2): 274-5
• Psychoneuroendocrine immunology: perception of stress can alter body temperature and natural killer cell activity. Hiramoto RN, Solvason HB, Hsueh CM, Rogers CF, Demissie S, Hiramoto NS, Gauthier DK, Lorden JF, Ghanta VK. Int J Neurosci. 1999; 98 (1-2): 95-129
• ECT in dissociative identity disorder and comorbid depression. DeBattista C, Solvason HB, Spiegel D. J ECT. 1998; 14 (4): 275-9
• Treatment of psychotic depression. Debattista C, Solvason HB, Belanoff J, Schatzberg AF. Am J Psychiatry. 1997; 154 (11): 1625-6
• A 25-year-old woman with hallucinations, hypersexuality, nightmares, and a rash. Stein SL, Solvason HB, Biggart E, Spiegel D. Am J Psychiatry. 1996; 153 (4): 545-51
• The identity of the unconditioned stimulus to the central nervous system is interferon-beta. Solvason HB, Ghanta VK, Hiramoto RN. J Neuroimmunol. 1993; 45 (1-2): 75-81
• A simple, single, trial-learning paradigm for conditioned increase in natural killer cell activity. Solvason HB, Ghanta VK, Soong SJ, Rogers CF, Hsueh CM, Hiramoto NS, Hiramoto RN. Proc Soc Exp Biol Med. 1992; 199 (2): 199-203
• Measurement of the thermal diffusivity of human epidermis by studying thermal wave propagation. Werner U, Giese K, Sennhenn B, Plamann K, Kölmel K. Phys Med Biol. 1992; 37 (1): 21-35
• A behavioral augmentation of natural immunity: odor specificity supports a Pavlovian conditioning model. Solvason HB, Ghanta VK, Lorden JF, Soong SJ, Hiramoto RN. Int J Neurosci. 1991; 61 (3-4): 277-88
• Conditioning: a new approach to immunotherapy. Ghanta VK, Hiramoto NS, Solvason HB, Soong SJ, Hiramoto RN. Cancer Res. 1990; 50 (14): 4295-9
• Conditioned augmentation of natural killer cell activity. Independence from nociceptive effects and dependence on interferon-beta. Solvason HB, Ghanta VK, Hiramoto RN. J Immunol. 1988; 140 (2): 661-5